Bristol-myers Squibb Compnay

Han Chang

Wen-Pin Yang

Alan J Korman

Mark J Selby

Mohan Srinivasan

John N Feder

Nils Lonberg

Jian Chen

Arvind Rajpal

Robert Peach

Steven B Kanner

Maria N Jure-Kunkel

Aaron Paul Yamniuk

Glen Eugene Mikesell

Kent B Thudium

Juan J Perez-Villar

Karla Ann Henning

Yuli Wu

Gena S Whitney

Mark F Maurer

Xi-Tao Wang

Indrani Chakraborty

Alexander T Kozhich

Patrick Guirnalda

Zhehong Cai

Shujian Wu

Brenda L Stevens

Michelle Minhua Han

Jochem Gokemeijer

Thomas D Kempe

Joshua N Finger

Michael Quigley

Susan Chien-Szu Wong

Guchen Yang

Hadia Lemar

Marie-Michelle Navarro Garcia

Henry Shen

Juan J Perez-villar

Liana M Lee

Bryan C Barnhart

Xiang Shao

Christina Maria Milburn

Michael A Blanar

Ning Lee

David K Bol

Ming Lei

Sandra V Hatcher

Liang Schweizer

William J Geese

Nathan O Siemers

Sabine Maier

Liana M Le

Zheng Yang

Nicholas Allan John Botwood

Joseph Daniel Szustakowski

Giovanni Selvaggi

Prabhu Seshaiyer Bhagavatheeswaran

Christine Huang

Yan Feng

Maria Rodriguez

The disclosure provides a method for treating a subject afflicted with a tumor derived from a small cell lung cancer (SCLC) having a high tumor mutational burden (TMB) status comprising administering to the subject a monotherapy comprising an anti-PD-1 antibody or a combination therapy comprising an anti-PD-1 antibody and an anti-CTLA-4 antibody. The present disclosure also provides a method for identifying a subject suitable for treatment with an anti-PD-1 antibody or a combination therapy comprising an anti-PD-1 antibody and an anti-CTLA-4 antibody comprising measuring a TMB status of a biological sample of the subject. A high TMB status identifies the patient as suitable for treatment with an anti-PD-1 antibody or antigen-binding portion thereof. The TMB status can be determined by sequencing nucleic acids in the tumor and identifying a genomic alteration, e.g., a somatic nonsynonymous mutation, in the sequenced nucleic acids.

Methods of treating tumor

Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Antibodies against OX-40 and uses thereof

Antibodies against OX40 and uses thereof

The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.

Growing community of inventors

Princeton Junction, NJ, United States of America

Han Chang